Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Pierluigi di Mauro"'
Regorafenib-related erythrocytosis in metastatic extra-gastrointestinal stromal tumor: a case report
Autor:
Elena Fassi, Vito Amoroso, Deborah Cosentini, Vittorio Ferrari, Marta Laganà, Alfredo Berruti, Pierluigi di Mauro
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionRegorafenib is an oral multi-targeted tyrosine kinase inhibitor (TKI) indicated for the treatment of various tumor types, including metastatic gastrointestinal stromal tumors (GIST), as a third-line systemic therapy. Erythrocytosis, which
Externí odkaz:
https://doaj.org/article/270a21599063485e850714719948f0e0
Autor:
Emma Zattarin, Luigi Mariani, Alice Menichetti, Rita Leporati, Leonardo Provenzano, Francesca Ligorio, Giovanni Fucà, Riccardo Lobefaro, Luca Lalli, Andrea Vingiani, Federico Nichetti, Gaia Griguolo, Marianna Sirico, Ottavia Bernocchi, Antonio Marra, Chiara Corti, Paola Zagami, Elisa Agostinetto, Flavia Jacobs, Pierluigi Di Mauro, Daniele Presti, Caterina Sposetti, Carlo Alberto Giorgi, Valentina Guarneri, Rebecca Pedersini, Agnese Losurdo, Daniele Generali, Giuseppe Curigliano, Giancarlo Pruneri, Filippo de Braud, Maria Vittoria Dieci, Claudio Vernieri
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Cyclin-Dependent Kinase 4/6 inhibitors (CDK4/6i) combined with Endocrine Therapy (ET) are the standard treatment for patients with Hormone Receptor-positive/HER2-negative advanced breast cancer (HR+/HER2− aBC). Objectives: While CDK4/6i
Externí odkaz:
https://doaj.org/article/997ec44c91b244349cd2462f6a583683
Autor:
Emma Zattarin, Daniele Presti, Luigi Mariani, Caterina Sposetti, Rita Leporati, Alice Menichetti, Chiara Corti, Chiara Benvenuti, Giovanni Fucà, Riccardo Lobefaro, Francesca Ligorio, Leonardo Provenzano, Andrea Vingiani, Marta Del Vecchio, Gaia Griguolo, Marianna Sirico, Ottavia Bernocchi, Antonio Marra, Paola Zagami, Elisa Agostinetto, Flavia Jacobs, Pierluigi Di Mauro, Andrea Esposito, Carlo Alberto Giorgi, Luca Lalli, Laura Boldrini, Pier Paolo Berton Giacchetti, Ambra Carnevale Schianca, Valentina Guarneri, Rebecca Pedersini, Agnese Losurdo, Alberto Zambelli, Daniele Generali, Carmen Criscitiello, Giuseppe Curigliano, Giancarlo Pruneri, Filippo de Braud, Maria Vittoria Dieci, Claudio Vernieri
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-5 (2023)
Abstract Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 pat
Externí odkaz:
https://doaj.org/article/1b8f8d9603654e7590deb24e3d8b863d
Autor:
Rebecca Pedersini, Pierluigi di Mauro, Vito Amoroso, Vincenza Castronovo, Manuel Zamparini, Sara Monteverdi, Lara Laini, Greta Schivardi, Deborah Cosentini, Salvatore Grisanti, Sara Marelli, Luigi Ferini Strambi, Alfredo Berruti
Publikováno v:
Breast, Vol 66, Iss , Pp 162-168 (2022)
Introduction: Whether adjuvant therapy with aromatase inhibitors (AIs) causes sleep disturbances or not in postmenopausal women with early breast cancer (EBC) is still a controversial issue. Methods: Between March 2014 and November 2017, validated qu
Externí odkaz:
https://doaj.org/article/99cd9dfa477048b8bb7ce1056066d7d3
Autor:
Rebecca Pedersini, Deborah Cosentini, Luca Rinaudo, Manuel Zamparini, Fabio Massimo Ulivieri, Pierluigi di Mauro, Filippo Maffezzoni, Sara Monteverdi, Walter Vena, Lara Laini, Vito Amoroso, Edda Lucia Simoncini, Davide Farina, Gherardo Mazziotti, Alfredo Berruti
Publikováno v:
Bone Reports, Vol 18, Iss , Pp 101654- (2023)
Background: Bone mineral density (BMD) lacks sensitivity in individual fracture risk assessment in early breast cancer (EBC) patients treated with aromatase inhibitors (AIs). New dual-energy X-ray absorptiometry (DXA) based risk factors are needed. M
Externí odkaz:
https://doaj.org/article/ba248560d4cc46be9270b812a4d5b509
Autor:
Pierluigi di Mauro, Greta Schivardi, Rebecca Pedersini, Lara Laini, Andrea Esposito, Vito Amoroso, Marta Laganà, Salvatore Grisanti, Deborah Cosentini, Alfredo Berruti
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundTriple-negative breast cancer (TNBC) is an aggressive cancer subtype, owing to its high metastatic potential: Patients who develop brain metastases (BMs) have a poor prognosis due to the lack of effective systemic treatments. Surgery and ra
Externí odkaz:
https://doaj.org/article/3cf7983c09e8463db74984731e41047e
Autor:
Rebecca Pedersini, Pierluigi di Mauro, Sara Bosio, Barbara Zanini, Alessandra Zanini, Vito Amoroso, Antonella Turla, Lucia Vassalli, Mara Ardine, Sara Monteverdi, Manuel Zamparini, Cristina Gurizzan, Deborah Cosentini, Chiara Ricci, Edda Lucia Simoncini, Alfredo Berruti
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract Change in eating habits in early breast cancer (EBC) patients during chemotherapy has been poorly studied in the literature. The primary aim of this study was to prospectively evaluate food preferences and weight change in EBC patients befor
Externí odkaz:
https://doaj.org/article/a5d7e99d50ab4bd186cb0d9642d9efe7
Autor:
Pierluigi di Mauro, Serena Capici, Viola Cogliati, Francesca Fulvia Pepe, Claudia Maggioni, Francesca Riva, Federica Cicchiello, Marina Elena Cazzaniga
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 6, Iss , Pp 100167- (2022)
Human epidermal growth factor receptor 2 (HER2) represents a crucial drug target in breast cancer treatment. Currently, several agents that target HER2 are available, including monoclonal antibodies, antibody-drug conjugates, and tyrosine kinase inhi
Externí odkaz:
https://doaj.org/article/bb7c80adb05f470aa7de8732da1c80e5
Autor:
Cristina Gurizzan, Rebecca Pedersini, Carla Fornaro, Chiara Sardini, Manuel Zamparini, Sara Monteverdi, Valeria Tovazzi, Deborah Cosentini, Alberto Dalla Volta, Alice Baggi, Antonella Turla, Pierluigi Di Mauro, Luigi Lorini, Marta Laganà, Susanna Bianchi, Salvatore Grisanti, Francesca Consoli, Elisabetta Conti, Paolo Bossi, Alfredo Berruti
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
ObjectiveTo evaluate the efficacy of clinical triage of oncological patients for safe continuation of cancer therapy implemented during the first SARS-CoV-2 outbreak.MethodsBetween 25 February and 21 April 2020, patients attending the Medical Oncolog
Externí odkaz:
https://doaj.org/article/7ec6514ad706451da5677f381a66a7ca
Autor:
Marco Merlano, Paolo Bossi, Cristina Gurizzan, Luigi Lorini, Pierluigi di Mauro, Chiara Sardini
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Externí odkaz:
https://doaj.org/article/c2c421e948884e2a9a737f39f41cabfb